AC Immune SA Files 20-F for FY 2024

Ticker: ACIU · Form: 20-F · Filed: Mar 13, 2025 · CIK: 1651625

Ac Immune SA 20-F Filing Summary
FieldDetail
CompanyAc Immune SA (ACIU)
Form Type20-F
Filed DateMar 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 20-F, annual-report, pharmaceuticals

TL;DR

AC Immune SA dropped its 2024 20-F, check financials.

AI Summary

AC Immune SA filed its 20-F report for the fiscal year ending December 31, 2024. The company, incorporated in V8 and headquartered at EPFL Innovation Park, Lausanne, Switzerland, operates in the Pharmaceutical Preparations sector. The filing includes financial data and operational details for the period.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of AC Immune SA's financial performance and business operations for the fiscal year 2024, crucial for assessing the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, AC Immune SA faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in its 20-F filing.

Key Numbers

Key Players & Entities

FAQ

What is AC Immune SA's primary business sector?

AC Immune SA operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].

Where is AC Immune SA headquartered?

AC Immune SA is headquartered at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

What is the SEC file number for AC Immune SA?

The SEC file number for AC Immune SA is 001-37891.

When was the 20-F filing submitted?

The 20-F filing was submitted on March 13, 2025.

What is the fiscal year end for AC Immune SA?

AC Immune SA's fiscal year ends on December 31.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on March 13, 2025 regarding AC Immune SA (ACIU).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing